Linked e-resources
Details
Table of Contents
Intro; Contents; 1 Strategies to Maintain Fertility in Young Breast Cancer Patients; Abstract; 1.1 Background; 1.2 Effects of Cancer Treatment on Fertility; 1.2.1 Oocyte Development and Fertility; 1.2.2 Chemotherapy; 1.2.3 Endocrine Therapies; 1.2.4 Bioimmune Therapy; 1.2.5 Radiation Therapy; 1.3 Oocyte and Embryo Cryopreservation; 1.3.1 Overview of Controlled Ovarian Stimulation; 1.3.2 Random-Start Protocols; 1.3.3 Use of Adjunct Aromatase Inhibitor; 1.3.4 Ovarian Hyperstimulation Syndrome; 1.4 Ovarian Suppression; 1.5 Ovarian Tissue Cryopreservation; 1.6 In Vitro Oocyte Maturation.
1.7 ConclusionReferences; 2 Adjuvant Endocrine Therapy; Abstract; 2.1 Introduction; 2.2 Biomarkers in HR-Positive Breast Cancer; 2.2.1 Hormone Receptors; 2.2.2 Molecular Profiling; 2.2.2.1 Molecular Profiling at Initial Diagnosis; 2.2.2.2 Molecular Profiling to Determine Benefit of Extended Adjuvant Endocrine Therapy; 2.3 Adjuvant Endocrine Therapy; 2.3.1 Menopausal Status; 2.3.2 Endocrine Therapy Classification; 2.3.2.1 Selective Estrogen Receptor Modulators; 2.3.2.2 Aromatase Inhibitors; 2.3.2.3 Ovarian Suppression; 2.3.3 Choice of Therapy Based on Menopausal Status.
2.3.3.1 Premenopausal Women2.3.3.2 Postmenopausal Women; 2.3.4 Duration of Therapy; 2.3.5 Male Breast Cancer; 2.3.6 Future Directions; 2.4 Conclusions; References; 3 Breast Cancer Screening: The Debate that Never Ends; Abstract; 3.1 Introduction; 3.2 United States Preventive Services Task Force (USPSTF); 3.3 American Cancer Society (ACS); 3.4 National Comprehensive Cancer Network (NCCN); 3.5 Discussion; References; 4 Management of the Axilla in Early Breast Cancer; Abstract; 4.1 Introduction; 4.2 History of Axillary Surgery; 4.3 Technical Considerations of SLNB; 4.4 The SLN Era.
4.4.1 Clinically Node-Negative Proof of Concept4.4.2 Clinically Node Negative with Positive SLNB; 4.5 Challenging Scenarios and Unanswered Questions; 4.5.1 Prophylactic Mastectomy; 4.5.2 Ductal Carcinoma in Situ; 4.5.3 Multicentric Lesions; 4.5.4 Elderly and Axillary Staging; 4.5.5 Prior Breast or Axillary Surgery; 4.5.6 Pregnancy; 4.6 Conclusion; References; 5 Is DCIS Overrated?; Abstract; 5.1 Introduction; 5.2 Anatomy; 5.3 Historical Perspectives on Natural History of DCIS; 5.4 Ductal Carcinoma in Situ and Invasive Ductal Carcinoma.
5.5 Clinical, Genomic, and Molecular Characteristics of DCIS5.6 Models of Invasion; 5.7 Incidence; 5.8 Natural History of DCIS; 5.9 Patient Perception of Risk and Treatment Choice; 5.10 Role of Radiation in DCIS; 5.11 Tools for Predicting Class in DCIS Treated with Breast Conservation; 5.12 Conclusion; References; 6 Readdressing the Role of Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer; Abstract; 6.1 Introduction; 6.2 Arguments for Local Therapy to the Primary Tumor; 6.3 Review of Retrospective Studies on Resection of Primary Tumor; 6.4 Bias in Retrospective Studies.
1.7 ConclusionReferences; 2 Adjuvant Endocrine Therapy; Abstract; 2.1 Introduction; 2.2 Biomarkers in HR-Positive Breast Cancer; 2.2.1 Hormone Receptors; 2.2.2 Molecular Profiling; 2.2.2.1 Molecular Profiling at Initial Diagnosis; 2.2.2.2 Molecular Profiling to Determine Benefit of Extended Adjuvant Endocrine Therapy; 2.3 Adjuvant Endocrine Therapy; 2.3.1 Menopausal Status; 2.3.2 Endocrine Therapy Classification; 2.3.2.1 Selective Estrogen Receptor Modulators; 2.3.2.2 Aromatase Inhibitors; 2.3.2.3 Ovarian Suppression; 2.3.3 Choice of Therapy Based on Menopausal Status.
2.3.3.1 Premenopausal Women2.3.3.2 Postmenopausal Women; 2.3.4 Duration of Therapy; 2.3.5 Male Breast Cancer; 2.3.6 Future Directions; 2.4 Conclusions; References; 3 Breast Cancer Screening: The Debate that Never Ends; Abstract; 3.1 Introduction; 3.2 United States Preventive Services Task Force (USPSTF); 3.3 American Cancer Society (ACS); 3.4 National Comprehensive Cancer Network (NCCN); 3.5 Discussion; References; 4 Management of the Axilla in Early Breast Cancer; Abstract; 4.1 Introduction; 4.2 History of Axillary Surgery; 4.3 Technical Considerations of SLNB; 4.4 The SLN Era.
4.4.1 Clinically Node-Negative Proof of Concept4.4.2 Clinically Node Negative with Positive SLNB; 4.5 Challenging Scenarios and Unanswered Questions; 4.5.1 Prophylactic Mastectomy; 4.5.2 Ductal Carcinoma in Situ; 4.5.3 Multicentric Lesions; 4.5.4 Elderly and Axillary Staging; 4.5.5 Prior Breast or Axillary Surgery; 4.5.6 Pregnancy; 4.6 Conclusion; References; 5 Is DCIS Overrated?; Abstract; 5.1 Introduction; 5.2 Anatomy; 5.3 Historical Perspectives on Natural History of DCIS; 5.4 Ductal Carcinoma in Situ and Invasive Ductal Carcinoma.
5.5 Clinical, Genomic, and Molecular Characteristics of DCIS5.6 Models of Invasion; 5.7 Incidence; 5.8 Natural History of DCIS; 5.9 Patient Perception of Risk and Treatment Choice; 5.10 Role of Radiation in DCIS; 5.11 Tools for Predicting Class in DCIS Treated with Breast Conservation; 5.12 Conclusion; References; 6 Readdressing the Role of Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer; Abstract; 6.1 Introduction; 6.2 Arguments for Local Therapy to the Primary Tumor; 6.3 Review of Retrospective Studies on Resection of Primary Tumor; 6.4 Bias in Retrospective Studies.